Press Enter to search Clear

Frequent Searches

Company Profile
Offices
Startup & Venture Capital
Capital Markets

Services Services
Corporate

Our Corporate Practices

Capital Markets

Compensation & Benefits

Corporate Governance

Corporate Venture

ESG & Sustainability

Mergers & Acquisitions

Private Equity

Private Investment Funds

Public Companies

SPACs

Startup & Venture Capital
Intellectual Property

Our Intellectual Property Practices

Copyright

Patents & Emerging Technologies

Privacy & Cybersecurity

Technology Transactions

Trademark
Litigation

Our Litigation Practices

Appellate

Complex Litigation

Consumer Class Actions & Mass Arbitration

Copyright Litigation

Employment

Patent Litigation

Patent Trial & Appeal Board (PTAB) Proceedings

Securities Enforcement

Securities Litigation

Trade Secret Litigation

Trademark Litigation

White Collar Defense & Investigations
Regulatory

Our Regulatory Practices

Antitrust & Competition

Government Contracts & Public Sector Procurement

Healthcare Regulatory

Fintech Regulatory

Trade & National Security
Tax

Our Tax Practices

FLEX by Fenwick

FLEX Overview
FLEX by Fenwick

FLEX Overview
Industries Industries
People People
About Us About Us
Firm

Firm Overview

Diversity

Service Innovation

Our Offices

Awards & Honors
Community

CSR Overview

Pro Bono

Fenwick Community Fund
Contact Us

Subscribe
Careers Careers
Careers

Careers Overview

Students

Experienced Attorneys

Business Professionals

Current Openings
Insights Insights
Insights

Our Insights

What's Trending

2025 CLE Speaker Series

Press Enter to search Clear

Frequent Searches

Company Profile
Offices
Startup & Venture Capital
Capital Markets

Back

Corporate

Our Corporate Practices
Capital Markets
Compensation & Benefits
Corporate Governance
Corporate Venture
ESG & Sustainability
Mergers & Acquisitions
Private Equity
Private Investment Funds
Public Companies
SPACs
Startup & Venture Capital

Intellectual Property

Our Intellectual Property Practices
Copyright
Patents & Emerging Technologies
Privacy & Cybersecurity
Technology Transactions
Trademark

Litigation

Our Litigation Practices
Appellate
Complex Litigation
Consumer Class Actions & Mass Arbitration
Copyright Litigation
Employment
Patent Litigation
Patent Trial & Appeal Board (PTAB) Proceedings
Securities Enforcement
Securities Litigation
Trade Secret Litigation
Trademark Litigation
White Collar Defense & Investigations

Regulatory

Our Regulatory Practices
Antitrust & Competition
Government Contracts & Public Sector Procurement
Healthcare Regulatory
Fintech Regulatory
Trade & National Security

Tax

Our Tax Practices
FLEX by Fenwick
FLEX Overview

FLEX by Fenwick

FLEX Overview

Back

Back

Back

Firm

Firm Overview
Diversity
Service Innovation
Our Offices
Awards & Honors

Community

CSR Overview
Pro Bono
Fenwick Community Fund

Contact Us

Subscribe

Back

Careers

Careers Overview
Students
Experienced Attorneys
Business Professionals
Current Openings

Back

Insights

Our Insights
What's Trending
2025 CLE Speaker Series

Our Insights

Publications

Corporate Partnerships with Universities and Patents

Our Insights

Publications

Corporate Partnerships with Universities and Patents

June 30, 2004

Corporate Partnerships with Universities and Patents

DuPont's Oncomouse patent licensing program continues to cause a stir in academia and industry.

Related Practices

Intellectual Property
Patents & Emerging Technologies

Share Subscribe

Related Insights

Publications What is the IP Risk Profile in AI Drug Discovery?

December 18, 2024

Publications Some AI-Discovered Drugs Carry More IP Risks Than Others—Here's Why

December 16, 2024

Publications AI & Drug Discovery: Key Patent Considerations

December 03, 2024

Experience Fenwick Advises Royalty Pharma and Pharmakon Advisors in their Agreements to Supply up to $375M in Funding to Geron Corporation

November 08, 2024

Publications False Claims of Patent Protection Can Be False Advertising Under Lanham Act

October 11, 2024

News Fenwick Garners Top Honors in Managing IP’s 2024 Guide

September 30, 2024

Experience Fenwick Represents Royalty Pharma in its up to €128.8M ($140M) Royalty Monetization Agreement with BRAIN Biotech AG

September 20, 2024

View more related insights

About Us
Locations
Press
Contact Us
Alumni

About Us

FLEX by Fenwick
Global Network
Locations

Careers

Alumni

Contact Us

Follow Us

Subscribe to Fenwick

My Fenwick Binder

© 2025 Fenwick & West LLP

Attorney Advertising

Attorney Advertising

Terms of Use

Terms of Use

Privacy Policy

Privacy Policy

Cookies Preferences

Cookies Preferences